Archive for the 'Actos' Category

Actos to be Withdrawn in France
Date Published: Tuesday, July 12th, 2011

French medicine regulators have banned diabetes drug Actos from their market citing study results which link the drug to an increased risk of bladder cancer. The French Health Products Safety Agency (AFSSAPS) announced Takeda’s drugs Actos and Compectact will be withdrawn in the country based on a French study showing an adjusted hazard ratio for bladder cancer among those taking the drug, reported InPharm.com.

The study was conducted by the nation’s insurance company and compared 155,000 patients in France taking pioglitazone, the generic version of Actos, from 2006 to 2009 to 1.3 million diabetics not using the drug. Researchers found a dose effect among those receiving a cumulative dosage of 28,000 mg or more resulting in an increased risk of bladder cancer. (more…)

Posted in Actos, Pharmaceuticals | No Comments »

Study Says Two Diabetes Drug Increase Risk of Eye Disease
Date Published: Monday, June 27th, 2011

Diabetes drugs Actos and Avandia may increase the risk of developing an eye disease that can lead to blindness, reported Bloomberg. A study to be presented Sunday at the American Diabetes Association’s annual meeting, reveals that patients taking either drug have a three to six times increased risk of developing diabetic macular edema (DME).

Actos and Avandia are known to increase the risk of fluid in the lungs and swelling in the legs; therefore, the study authors concluded “patients at high risk of sight-threatening DME should avoid” drugs such as Actos and Avandia. Those at high-risk include patients with issues controlling their blood sugar and those with a previous history of macular edema. (more…)

Posted in Actos, Avandia, Pharmaceuticals | No Comments »